Trimazosin hydrochloride

This classification denotes the hydrochloride form of an alpha-adrenergic blocking agent with the molecular formula C20H29N5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 31L760807H, chemically known as 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylic acid, 2-hydroxy-2-methylpropyl ester but more generally known as trimazosin, which bears US NIH Compound Identifier 37264. European Medicines Agency schedules Trimazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11298MIG. The term TRIMAZOSIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). World Health Organization schedules trimazosin in its Anatomical Therapeutic Chemical (ATC) Classification. TRIMAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule trimazosin hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, TRIMAZOSIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Trimazosin hydrochloride bears US NLM identifiers UMLS ID C0888485 and NCI Concept Code C75060. SMILES: CC(C)(COC(=O)N1CCN(CC1)C2NC3C(CC(C(C3OC)OC)OC)C(N2)N)O.O.CL.